- 23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data.
- 23andMe is now restructuring its business operations to reduce costs and streamline operations.
- A 23andMe spokesperson said the company is “consistently focused on maintaining the privacy of our customers.”
23andMe CEO Anne Wojcicki sounded optimistic about the company’s future during an earnings call in February last year.
She said the biotech company, which offers direct-to-consumer genetic testing, made strides with its new preventive care membership service, signed a $20 million research agreement with biopharma company GSK, and saw “repeated engagement” by its customers, among other triumphs.
Then the rest of the year happened.
Here’s a breakdown of what went wrong for 23andMe.
Source link
lol
